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Abstract 
Introduction: Recombinant α(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients
with α(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may func-
tion as a chemoattractant. The migratory effects of yeast-derived human recombinant α(1)-proteinase inhibitor on human
peripheral blood neutrophils and eosinophils were therefore tested in vitro.
Materials and Methods: Human peripheral blood leukocytes were prepared from forearm venous blood and tested for migra-
tion toward various preparations of yeast-derived recombinant α(1)-proteinase inhibitor in modified Boyden-chamber
micropore filter assays.
Results: No direct effects of yeast-derived recombinant human α(1)-proteinase inhibitor on in vitro migration of isolated neu-
trophils or eosinophils were seen. 
Conclusions: The lack of direct chemotactic effects of recombinant human α(1)-proteinase inhibitor despite anti-inflamma-
tory effects in other biological activities of leukocytes may contribute to the preserved antibacterial defense mechanisms
observed in patients under experimental augmentation therapy with inhaled α(1)-proteinase inhibitor.
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INTRODUCTION
In the healthy human lung, α(1)-proteinase inhibitor
(A1PI) is present at high concentrations and acts as an
anti-protease screen to prevent the deleterious effects of
free elastase [2]. People with a deficiency of A1PI are at
risk for emphysema as a result of low levels of A1PI in the
lungs in the presence of neutrophil elastase [25]. In cystic
fibrosis airways, A1PI is complexed [3] and proteolytical-
ly inactivated [26], resulting in an imbalance of proteases
and anti-proteases. The discovery of the structure and
function of the A1PI protein and its subsequent isolation
and purification have allowed replacement therapy (so-
called “augmentation therapy”) aimed at preventing the
progression of the lung disease associated with deficiency
or cystic fibrosis [9]. Isolation of the gene and advances in
gene therapy further broadened the potential for specific
therapy by the synthesis of recombinant A1PI.
Therapeutic concentrates are prepared from the
blood plasma of blood donors and are the only form of
A1PI available for therapy so far. All commercially
available A1PI products differ from the A1PI directly
analyzed in plasma (summarized in Table 1). The
observed differences between the products most likely
do not play a substantial biologic role because all three
products have similar half-lives in humans and neutral-
ize neutrophil elastase to the same extent [12].
To attenuate the deleterious effects of free elastase
on pulmonary structure and host defense mechanisms
more effectively, the inhalation of A1PI has been pro-
posed as a therapeutic strategy in both A1PI deficiency
and cystic fibrosis patients. Inhalation of human plasmat-
ic A1PI increased A1PI levels in adult patients with cystic
fibrosis and decreased the levels of elastase activity, neu-
trophils, pro-inflammatory cytokines, and the numbers of
Pseudomonas aeruginosa [7]. Trends of reduced elastase
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levels and inflammation had already been observed in
another study using recombinant A1PI [16].
Recombinant technology has also been used to pro-
duce human A1PI [4, 11, 14, 17], as regulatory authori-
ties have recommended the development of recombi-
nant counterparts to blood-derived therapeutic human
proteins [18]. Recombinant A1PI is not yet commercial-
ly available, but it is under investigation as a therapy for
A1PI deficiency for both intravenous application and
inhalation. In the development of drug therapy for A1PI
deficiency, aerosol administration of recombinant pro-
teins to the airways has been the preferred method of
delivery because of their shorter half-lives after intra-
venous infusion compared with that of A1PI purified
and concentrated from human plasma [5].
Recent studies suggest a role for A1PI as an anti-
-inflammatory modulator [19] independent of its
antiproteinase effect, which may explain some of the
observations in recent clinical studies. A1PI inhibited
lipopolysaccharide (LPS)-induced tumor necrosis fac-
tor-α and interleukin (IL)-1β release from monocytes
dose dependently and IL-8 release from neutrophils in
vitro. Furthermore, A1PI instillation after LPS chal-
lenge prevented LPS-induced IL-8 production in vivo
[19]. It is currently unknown to what extend recombi-
nant A1PI affects leukocyte chemotaxis. Alteration of
leukocyte migration could have relevance to the cells’
pulmonary accumulation, which is of major pathophysi-
ological importance [10]. We therefore investigated the
direct effects of human recombinant (rh)A1PI on
human peripheral blood granulocyte chemotaxis in vitro.
We report that rhA1PI from yeast does not induce in
vitro chemotaxis of leukocytes in micropore filter assays. 
MATERIALS AND METHODS
rhA1PI preparation and other material 
The rhA1PI used in this study, supplied by Baxter
(Vienna, Austria), was produced by yeast transformed
with an expressing plasmid containing a human cDNA
encoding the mature normal Ml (Val213) human A1PI
protein [21]. This rhA1PI preparation has a molecular
mass of about 45 kDa, similar to human plasma A1PI,
and functions in an identical manner as human plasma
rhA1PI as an inhibitor of neutrophil elastase [1].
Formyl-Met-Leu-Phe, dextran, and penicillin-strepto-
mycin were from Sigma Chemical Corp. (St. Louis, MO,
USA). RANTES was from Pepro Tech EC Ltd. (London,
UK). RPMI 1640 with phenol red purchased from
Biochrom AG (Berlin, Germany). Bovine serum albumin
(BSA) was from Dade Behring (Marburg, Germany).
Lymphoprep was from Nycomed Pharma AS (Oslo,
Norway). MACS separation columns and microbeads
were from Miltenyi Biotech (Auburn, CA, USA). Fetal
calf serum and phosphate-buffered saline (PBS) were
from PAA Laboratories GmbH (Pasching, Austria).
Trypsin-EDTA in HBSS from Gibco (Paisley, UK). The
microchemotaxis chambers were from Neuroprobe
(Bethesda, MD, USA) and the cellulose nitrate filters
were from Sartorius (Goettingen, Germany). 
Preparation of granulocytes
Neutrophils and eosinophils were obtained from
peripheral EDTA-anticoagulated blood of healthy volun-
teers by Lymphoprep density gradient centrifugation
followed by dextran sedimentation and hypotonic lysis of
contaminating erythrocytes as described previously [6].
The neutrophil preparations yielded above 95% neu-
trophils (by morphology in GIEMSA stains) of more than
99% viability (by trypan dye exclusion). For the
eosinophil preparation, the cells were resuspended in 50
ml of ice-cold MACS buffer (PBS with 5 mmol/l EDTA
and 0.5% BSA) per 5×107 cells and an equal volume of
MACS colloidal superparamagnetic microbeads conju-
gated with monoclonal anti-human CD16 monoclonal
antibody was added and incubated (30 min, 4°C).
Recommended volumes of ice-cold MACS buffer were
added to the cell-microbead mixture and the cell suspen-
sion was loaded onto the separation column. The eluate
containing CD16-negative eosinophils was collected,
washed, resuspended in RPMI 1640/0.5% BSA, and the
separation procedure was repeated to increase purity.
The purity of the sorted eosinophils was 98% as deter-
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Table 1. Human plasmatic α-1-antitrypsin preparation modifications1
Aralast Prolastin Zemaira
Company Baxter Healthcare Talecris Biotherapeutics CSL Behring
Plasma half-lives (days) 5.9±1.2 5.1±0.5 5.1±2.4
Specific activity (mg functional A1PI/mg protein)* ≥0.55 ≥0.35 ≥0.07
Glycoisoforms No major difference
Deamidation (qualitative) Detectable
Deamidation (quantitative, %) 6 10 7
C-terminal Lys truncation (%) 67 2 6
Cys232 cysteinylation + + –
Methionin oxidation Not observed (A1PI fully functional active)
1 Data in part taken from product specifications or from Kolarich et al. [12].
* Plasma A1PI, 0.02.
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mined by morphology and FACS analysis. Contaminating
cells were 1% lymphocytes, 1% neutrophils and baso-
phils, and negligible numbers of monocytes/macrophages.
Migration assay 
The migration assays were performed using a modi-
fied 48-well Boyden microchemotaxis chamber
(Neuroprobe, Bethesda, MD, USA) in which a 5-µm-
-pore-size cellulose nitrate filter separated the upper and
lower chambers [6]. Neutrophils or eosinophils were
resuspended in RPMI 1640/0.5% BSA (1×106 cells/ml).
Fifty µl of the cell suspension were placed into the upper
chamber and allowed to migrate toward 10 nmol/l of
formyl-Met-Leu-Phe or toward 10 ng/l of RANTES
chemokines, which were used as positive-control
chemoattractants at optimal concentrations for neu-
trophils and eosinophils, respectively; various dilutions
of rhA1PI probes 1–4; or respiratory cell culture super-
natants placed in the lower chamber for 30 min (neu-
trophils) or 60 min (eosinophils) at 37°C in a humidified
atmosphere (5% CO2). After the migration period, the
nitrocellulose filters were dehydrated, fixed, and stained
with hematoxylin. The migration depth of the cells into
the filters was quantified by means of microscopy, mea-
suring the distance (µmm) from the surface of the filter
to the leading front of three cells. Data are expressed as
the chemotaxis index, which is the ratio of the distances
of directed and random migration of neutrophils or
eosinophils into the nitrocellulose filters.
Statistical methods
Data are expressed as mean ± standard error of the
mean (SEM). Means were compared by the Mann-
-Whitney U-test and Kruskal-Wallis ANOVA. A differ-
ence with p<0.05 was considered to be significant.
Statistical analyses were performed using the StatView
software package (Abacus Concepts, Berkeley, CA,
USA).
RESULTS AND DISCUSSION
To investigate whether granulocyte recruitment to
the lung could be a direct effect of rhA1PI, in vitro neu-
trophil or eosinophil chemotaxis was assessed. The
human plasmatic A1PI protein in a range of concentra-
tions from 0.1–3 mg/ml had no effect on granulocyte
chemotaxis (data not shown). Data from different
preparations of yeast rhA1PI and a vehicle (MOCK)
preparation which contained the preparation’s solution
but devoid of the protein are shown for neutrophils (Fig.
1) and for eosinophils (Fig. 2). The positive-control
attractants 10 nmol/l of formyl-Met-Leu-Phe and 10
ng/l of RANTES for neutrophils and eosinophils,
respectively, significantly stimulated directed migration.
Neither of the rhA1PI preparations affected migration
in a significant manner at doses ranging from attomo-
lar to micromolar concentrations. The MOCK prepara-
tion had no effect on eosinophil migration. It stimulated
neutrophil directed migration to some extent, reach-
ing statistical significance at the highest dose tested, cor-
responding to the rhA1PI vehicle concentration of 
>1 µmol/l. 
Inhaled rhA1PI may directly contribute to leukocyte
accumulation in the lung as human plasmatic A1PI may
function as a neutrophil chemoattractant when poly-
merized [15, 20, 22]. However, no direct effect was seen
for rhA1PI on neutrophil or eosinophil chemotaxis.
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Fig. 1. Human peripheral blood neutrophil
migration toward the chemoattractant
formyl-Met-Leu-Phe or α(1)-antitrypsin
(rAAT). Mean distances of random migra-
tion were 66, 77, 74, and 85 µm for rAAT-1,
rAAT-2, rAAT-3, and MOC, respectively.
*p<0.05, Mann-Whitney U-test versus me-
dium after multiple group comparison by
using the Kruskal-Wallis test.
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Polymerization of rhA1PI has not been reported so far;
consequently, induction of migration by rhA1PI if poly-
merized remains speculative. The present results indi-
cate, however, that at high concentrations, a crude
preparation of vehicle (MOCK) induced human neu-
trophil, but not eosinophil migration to some extent,
suggesting the potential of eventual contaminants to
modify migration. Since eosinophils did not respond to
the vehicle, the contaminating compound(s) may be
specific and involve molecular mechanisms. As the
rhA1PI was unable to induce the same effect, it may be
that the dose equivalence between the two types of sam-
ples was not given. Another possibility is that the
immunomodulatory activity of rhA1PI on leukocytes
heterogeneously cross-deactivates chemotactic contam-
ination of the vehicle, such as that described between
non-chemotactic tumor necrosis factor-alpha and
chemokines [24]. Despite the application of good man-
ufacturing practice, contamination of the yeast-derived
rhA1PI formulation may thus potentially induce inflam-
matory responses after aerosol inhalation. Host
responses to yeast are mediated by Toll-like receptor 2
(TLR2), which is normally expressed by a variety of
human cells. Cell-surface TLR2 activation is known to
induce neutrophil activation. In vivo indirect chemotac-
tic effects may be exerted by induced mediators that are
released from respiratory cells, including IL-8, which is
a potent granulocyte attractant responsible for leuko-
cyte accumulation in lung airways [8, 13]. Thus for the
evaluation of safety, direct and indirect mechanisms by
which aerosol inhalation of yeast-derived rhA1PI for-
mulations may adversely affect lung inflammation have
to be taken into account. 
Given the concerns related to the limited supply of
pooled human plasma and the potential for the trans-
mission of infectious agents, some manufacturers are
particularly investigating alternative sources of augmen-
tation therapy. Transgenic or recombinant sources
could be used in inhalation devices. Yeast expression
systems are well suited for the production of rhA1PI.
Yeast rhA1PI manufactured in Saccharomyces cerevisiae
(baker’s or brewer’s yeast) [4] was tested in a clinical
trial when administered by aerosol inhalation to patients
with rhA1PI deficiency associated with hereditary
emphysema. According to the sponsors’ information,
results from this phase 1A human study evaluating safe-
ty and immunogenicity showed that rhA1PI was well tol-
erated and a phase 1B/2A clinical trial has been said to
be underway to evaluate its effects [1].
rhA1PI from yeast does not induce in vitro chemo-
taxis of granulocytes in micropore filter assays. Contents
in the preparation’s vehicle from yeast may still have the
potential to induce migration of leukocytes because
TLR-2 on other airway cells may indirectly contribute to
leukocyte accumulation by release of leukocyte attrac-
tants such as IL-8. In consequence, the proinflammato-
ry potential of rhA1PI aerosol therapy will have to be
assessed clinically in order to assure its safety. There
remains the need for high standards for purification of
recombinant proteins.
Strategies to evaluate immune-mediated toxic
effects of preparations of transgenic protein should be
established to ensure the development of safe and effec-
tive therapies. To evaluate the safety of sheep-derived
transgenic rhA1PI, aerosolized sheep-derived trans-
genic rhA1PI was administered in two clinical studies
[23]. Systemic antibody responses to non-human protein
that was present in very low concentrations in a sheep-
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Fig. 2. Human peripheral blood
eosinophil migration toward the
chemoattractant RANTES or α(1)-anti-
trypsin (rAAT). Mean distances of ran-
dom migration were 62, 68, 69, and 72
µm for rAAT-1, rAAT-2, rAAT-3, and
MOC, respectively. *p<0.05, Mann-
-Whitney U-test versus medium after
multiple group comparison by using the
Kruskal-Wallis test.
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-derived transgenic rhA1PI formulation were observed
after aerosol inhalation. The clinical symptoms and sec-
ondary antibody responses suggest that re-exposure
could result in intolerance of non-human-protein impu-
rities [23]. These observations may represent an impor-
tant obstacle to the development of transgenic human
proteins for therapeutic use.
In conclusion, the present study explored if rhA1PI
directly activates lung inflammatory granulocyte migra-
tion. The result of no direct chemotactic effects of A1PI
despite its recently described anti-inflammatory affects
in other biological activities of leukocytes may explain
the preserved antibacterial defense mechanisms
observed in patients under experimental inhalative aug-
mentation therapy with rhA1PI.
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